CN113025580B - 一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体和抗体的应用 - Google Patents
一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体和抗体的应用 Download PDFInfo
- Publication number
- CN113025580B CN113025580B CN202110271245.8A CN202110271245A CN113025580B CN 113025580 B CN113025580 B CN 113025580B CN 202110271245 A CN202110271245 A CN 202110271245A CN 113025580 B CN113025580 B CN 113025580B
- Authority
- CN
- China
- Prior art keywords
- fipronil
- monoclonal antibody
- hybridoma cell
- cell strain
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005899 Fipronil Substances 0.000 title claims abstract description 127
- 229940013764 fipronil Drugs 0.000 title claims abstract description 127
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 21
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000012360 testing method Methods 0.000 claims abstract description 13
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000008157 ELISA kit Methods 0.000 claims abstract description 8
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 7
- 238000001514 detection method Methods 0.000 claims description 28
- 238000002965 ELISA Methods 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 10
- 238000004458 analytical method Methods 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000000447 pesticide residue Substances 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 29
- 238000000034 method Methods 0.000 description 18
- 239000011248 coating agent Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000013307 optical fiber Substances 0.000 description 11
- 230000003053 immunization Effects 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000037029 cross reaction Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- 244000309466 calf Species 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000575 pesticide Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006013 carbendazim Substances 0.000 description 3
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 3
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- WCXDHFDTOYPNIE-RIYZIHGNSA-N (E)-acetamiprid Chemical compound N#C/N=C(\C)N(C)CC1=CC=C(Cl)N=C1 WCXDHFDTOYPNIE-RIYZIHGNSA-N 0.000 description 1
- -1 2, 6-dichloro-4-trifluoromethylphenyl Chemical group 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- OEDUIFSDODUDRK-UHFFFAOYSA-N 5-phenyl-1h-pyrazole Chemical compound N1N=CC=C1C1=CC=CC=C1 OEDUIFSDODUDRK-UHFFFAOYSA-N 0.000 description 1
- 239000005875 Acetamiprid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/18—Water
- G01N33/1826—Organic contamination in water
- G01N33/184—Herbicides, pesticides, fungicides, insecticides or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明属于免疫学和农药残留分析的技术领域,本发明提供了一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体和抗体的应用。本发明提供的抗氟虫腈单克隆抗体的杂交瘤细胞株F‑3F6,保藏于中国典型培养物保藏中心,地址:中国武汉,武汉大学,保藏日期为2021年2月9日,保藏编号CCTCC NO:C202157;所述抗氟虫腈单克隆抗体,由所述抗氟虫腈单克隆抗体的杂交瘤细胞株F‑3F6产生。本发明提供的抗氟虫腈单克隆抗体可用于制备检测氟虫腈的酶联免疫试剂盒、胶体金层析试纸条和倏逝波荧光免疫传感器,以达到快速且灵敏地检测食品和环境中的氟虫腈药物的目的。
Description
技术领域
本发明涉及免疫学和农药残留分析的技术领域,尤其涉及一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体和抗体的应用。
背景技术
氟虫腈(Fipronil),化学名称5-氨基-3-腈基-1-2-(2,6-二氯-4-三氟甲基苯基)-4-三氟甲基亚酰胺基苯唑,是一种苯基吡唑类杀虫剂,可作用于α-氨基丁酸受体(GABA),阻断由GABA控制的神经膜氯离子通道,对多种害虫具有防治作用。进一步研究发现,该类农药不仅仅对害虫等无脊椎动物有危害作用,对哺乳动物等脊椎动物也有巨大危害,已有研究证实氟虫腈对肝脏和肾脏有很高的毒性,世界卫生组织(WHO)已将其列为“对人类有中度毒性”的化学品。2017年8月,由氟虫腈残留所造成的“毒鸡蛋”事件在欧洲地区掀起一场食品安全危机。鉴于此类事件的不断发生,世界各国食品安全机构均对农产品中氟虫腈的最大残留量(MRL)制定了严格的限量规定,国际食品法典委员会(CAC)规定不同食品及饲料中氟虫腈的限量为0.02mg/kg~0.5mg/kg,其中蛋类的限量为0.02mg/kg。我国在GB2763-2016《食品安全国家标准食品中农药最大残留限量》中规定了氟虫腈在24项植物源性食品中残留限量标准,限量为0.02mg/kg~0.1mg/kg。
鉴于此类危害,国内外相关部门不断加大对食品和环境中的该类农药残留管理和监测力度,投入了大量技术、资金和人力来开发和应用该类药物残留分析技术。目前,对于氟虫腈残留检测方法主要集中在高效液相色谱法(HPLC)、气相色谱法(GC)、液相色谱-串联质谱法(LC-MS/MS)、气相色谱-质谱法(GC-MS)、电子捕获和质谱检测的气相色谱法(GC-ECD)等仪器方法的检测研究上。该类方法具有一定的灵敏度和准确度,但同时存在着仪器昂贵、速度不快、操作繁琐、高通量不够、不能现场检测等技术瓶颈,严重影响了在现场快速检测和实际批量分析中的应用。然而,对于快速筛查氟虫腈的分析方法,目前还都不成熟,探究原因,高特异性、高灵敏的优良功能性生物材料的获得是限制其发展的主要瓶颈。因此,制备高特异性、高敏感性抗氟虫腈单克隆抗体,获得性能优良的生物功能材料,对于解决小分子农药快检技术瓶颈背后的核心问题,建立氟虫腈现场即时并行检测技术,具有重大的理论意义和现实意义。
发明内容
本发明所要解决的技术问题是克服现有检测技术的缺陷提供一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体。所述抗氟虫腈单克隆抗体对氟虫腈药物具有特异性,本发明将该单克隆抗体应用于检测食品及环境中残留的氟虫腈药物。
为了实现上述发明目的,本发明提供了一种抗氟虫腈单克隆抗体的杂交瘤细胞株F-3F6,保藏于中国典型培养物保藏中心,地址:中国武汉,武汉大学,保藏日期为2021年2月9日,保藏编号CCTCC NO:C202157。
本发明还提供了一种抗氟虫腈单克隆抗体,由所述抗氟虫腈单克隆抗体的杂交瘤细胞株F-3F6产生。
本发明还提供了一种所述抗氟虫腈单克隆抗体在非诊断和治疗目的的检测氟虫腈中的应用。
本发明还提供了一种所述抗氟虫腈单克隆抗体用于制备检测氟虫腈的检测产品中的应用。
优选的,所述检测产品包括酶联免疫试剂盒、胶体金层析试纸条、倏逝波荧光免疫传感器。
本发明还提供了一种检测氟虫腈的酶联免疫试剂盒,所述酶联免疫试剂盒包括所述的抗氟虫腈单克隆抗体。
本发明还提供了一种检测氟虫腈的胶体金层析试纸条,所述胶体金层析试纸条包括所述的抗氟虫腈单克隆抗体。
本发明还提供了一种检测氟虫腈的倏逝波荧光免疫传感器,所述倏逝波荧光免疫传感器包括所述的抗氟虫腈单克隆抗体。
本发明提供的杂交瘤细胞株F-3F6分泌产生的抗氟虫腈单克隆抗体效价为1:2048000,亚型为IgG1,亲和力常数Ka=4.6×1010L/mol,对氟虫腈抑制率IC50为0.32μg/L,与氟虫腈的交叉反应率为100.00%,与克百威、多菌灵等农药的交叉反应率均小于0.01%。该抗体可用于非诊断和治疗目的的氟虫腈的检测,主要是将其应用于制备检测氟虫腈的酶联免疫试剂盒、胶体金层析试纸条和倏逝波荧光免疫传感器,以达到快速且灵敏地检测食品和环境中的氟虫腈药物的目的。本发明提供的抗氟虫腈单克隆抗体的质量具有很强的可控性和可重复性,并通过对所得抗体特性的初步分析及鉴定,为特异、灵敏的氟虫腈免疫测定方法的进一步建立和应用提供了实验依据和基础原料。
附图说明
图1为本发明实施例1制备的氟虫腈人工抗原凝胶电泳鉴定图;
图2为本发明实施例1制备的氟虫腈免疫原紫外扫描鉴定图;
图3为本发明实施例2制备的抗氟虫腈单克隆抗体亚型测定图;
图4为本发明实施例2制备的抗氟虫腈单克隆抗体亲和力测定图;
图5为本发明实施例2制备的抗氟虫腈单克隆抗体抑制率曲线图。
保藏说明
抗氟虫腈单克隆抗体的杂交瘤细胞株F-3F6,保藏于中国典型培养物保藏中心,地址:中国武汉,武汉大学,保藏日期为2021年2月9日,保藏编号CCTCC NO:C202157。
具体实施方式
下面结合实施例对本发明提供的技术方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1氟虫腈人工抗原的制备
(1)免疫原的制备
称取氟虫腈20mg溶解到3mL DMF(二甲基甲酰胺)中,加入10%的戊二醛溶液90μL,在室温下搅拌10min。称取50mg BSA(牛血清白蛋白)用10mL 0.01M的PBS溶解后,加入等量pH为8.6的硼酸盐缓冲液。在冰浴中逐滴混匀。冰浴下搅拌过夜。透析即得免疫原F-BSA。
(2)包被原的制备
包被原的制备过程与免疫原的制备过程相同,区别仅在于将牛血清白蛋白替换成卵清白蛋白,制得包被原F-OVA。
对制备的氟虫腈人工抗原进行鉴定:
SDS-PAGE鉴定
对免疫原F-BSA、包被原F-OVA,以及氟虫腈类似物的免疫原FH-BSA和氟虫腈类似物的包被原FH-OVA进行SDS-PAGE鉴定。按照常规SDS-PAGE方法,配制12%分离胶,5%浓缩胶,电压30V至蛋白条带进入分离胶后,调节电压90V继续电泳约2h。经染色、脱色处理。结果见图1,偶联产物F-BSA与BSA有明显差别,带宽且有拖尾,判定F-BSA偶联成功。
紫外分光光度法鉴定
用PBS对氟虫腈(F)和BSA进行适当稀释,测定BSA的蛋白浓度,把F-BSA稀释到与BSA相同浓度,在280nm波长下进行紫外扫描。结果见图2,BSA、氟虫腈(F)的最大吸收峰在289.1和306.7,BSA与F偶联后两者的峰叠加在283.6处有最大吸收峰,表明偶联成功。依据朗伯-比尔定律,推算出F-BSA的偶联比约为2.75:1。
实施例2抗氟虫腈单克隆抗体的制备
(1)动物免疫
取实施例1制备的免疫原F-BSA免疫6~8周龄的雌性Balb/c小鼠,间隔2周免疫1次,免疫流程见表1,三次免疫后断尾取血测定效价和抑制率,选择结果最佳的小鼠加强免疫,选择结果最佳的小鼠作为融合小鼠。
表1免疫流程表
免疫时间 | 免疫次数 | 免疫部位 | 免疫剂量 | 备注 |
0 | 第一次免疫 | 尾静脉注射 | 10μg/只 | |
2周 | 第二次免疫 | 尾静脉注射 | 10μg/只 | |
4周 | 第三次免疫 | 尾静脉注射 | 10μg/只 | 测定效价、抑制率 |
6周 | 加强免疫 | 尾静脉注射 | 10μg/只 |
(2)细胞融合
取步骤(1)中选定的融合小鼠摘眼球放血,脱颈处死后无菌条件下取出脾脏,制备脾细胞,与SP2/0细胞按5:1的比例通过PEG融合,将融合后的细胞悬液加入已铺有饲养细胞的96孔板,放入37℃、5%CO2的培养箱中培养。
(3)阳性杂交瘤细胞株的筛选
融合后的细胞,次日检查有无污染,融合后第10d换用HT培养基。换液后3d用间接ELISA和间接竞争ELISA进行阳性孔筛选,挑选出强阳性、抑制率高、单个克隆、细胞状态好的孔,通过有限稀释法进行亚克隆,同时进行扩大培养,直至建立单一分泌抗氟虫腈抗体的单克隆细胞株F-3F6。
(4)抗氟虫腈单克隆抗体的制备与纯化
采用小鼠体内诱生腹水的方法,取健康的Balb/c雌性小鼠,每只小鼠体内注射石蜡油0.5mL,7d后调整克隆化阳性杂交瘤细胞106/mL,每只小鼠腹腔注射1mL,8d后取腹水,离心弃脂肪,先后经辛酸-硫酸铵、ProteinA亲和层析柱纯化,冻干后-20℃保存,即得纯化的抗氟虫腈单克隆抗体。
对制备的抗氟虫腈单克隆抗体的特性进行鉴定
1.效价测定
采用常规间接ELISA法测定效价。将包被原F-OVA用碳酸盐缓冲液(CBS)稀释为5μg/mL,100μL/孔加入到酶标板孔中,4℃放置过夜。用Thermo洗板机洗涤酶标板3次,甩干。用洗液配置10%小牛血清溶液,200μL/孔加入酶标板孔,37℃孵育1h。洗板。用缓冲液将纯化的抗氟虫腈单克隆抗体倍比稀释成1:2000,1:4000,1:8000,1:16000,1:32000,1:64000,1:128000,1:256000,1:512000,1:1024000,1:2048000,1:4096000,以不加血清孔为阴性对照,100μL/孔,37℃避光孵育45min。洗板。用含有10%小牛血清的缓冲液按1:10000稀释山羊抗小鼠的二抗,100μL/孔,37℃避光孵育30min。洗板。加入底物显色液,100μL/孔,37℃避光孵育10min。加入终止液,50μL/孔,在酶标仪450nm下读数,阴性对照孔A值为N,各待测阳性孔为P。以P/N≥2.1作为测定效价的结果。抗氟虫腈单克隆抗体F-3F6浓度为1mg/mL时的效价达1:2048000。
(2)亚型测定
采用购自Sigma公司的鼠源单抗亚型鉴定试剂盒进行亚型测定。杂交瘤细胞分泌的抗氟虫腈单克隆抗体与不同亚类的二抗显色有明显差异,其中与IgG1二抗的A450nm值最高,与IgM的二抗显色微弱,而与IgG2a、IgG2b、IgG3和IgA二抗几乎不显色,因此,该杂交瘤细胞分泌的抗体类型以IgG1为主,结果见图3。所以本发明的抗氟虫腈单克隆抗体亚型为IgG1。
(3)亲和力测定
采用非竞争ELISA法测定亲和常数(Ka)。具体步骤如下:包被:用碳酸盐缓冲液稀释包被原F-OVA至浓度为1、0.5、0.25、0.125μg/mL,96孔酶标板100μL/孔分别包被,4℃过夜;倾去包被液,洗涤3次,拍干。封闭:每孔加200μL含10%小牛血清的洗液,37℃孵育1h;倾去封闭液,洗涤3次,拍干。加单抗(即本实施例制备的抗氟虫腈单克隆抗体):用洗液将单抗以100μg/mL开始倍比稀释,每孔加入100μL,37℃保温保湿45min;倾去一抗,洗涤3次,拍干。加酶标二抗:每孔加入100μL的l:10000倍稀释的HRP酶标记的山羊抗鼠IgG,37℃放置30min;倾去酶标二抗,洗涤3次,拍干。显色:每孔加底物显色液100μL,37℃避光反应15min。终止:每孔加入50μL终止液,终止反应。检测:测定波长为450nm处的吸光度值(A450nm)。按下列公式计算Ka,
Ka=(n-1)/2(nAb’-Ab);
式中:Ab为抗原浓度为Ag时,产生半数吸光度值的抗体浓度;Ab’为抗原浓度为Ag’时,产生半数吸光度值的抗体浓度;n为Ag和Ag’之间的稀释倍数。采用非竞争酶联免疫法测定氟虫腈单克隆抗体的亲和常数,结果如图4所示,计算亲和常数Ka=4.6×1010L/mol。
(4)抑制率测定
抑制率测定采用间接竞争ELISA法。具体步骤如下:包被:用碳酸盐缓冲液稀释包被原F-OVA至浓度为5μg/mL,96孔酶标板100μL/孔,4℃过夜;倾去包被液,洗涤3次,拍干;封闭:每孔加200μL含10%小牛血清的洗液,37℃孵育1h;倾去封闭液,洗涤3次,拍干;加单抗和氟虫腈标准品:将氟虫腈标准品母液用PBS稀释成2.0、1.0、0.50、0.25、0.125、0μg/L,每孔加入50μL,再加入一定稀释倍数(1:64000倍)的单抗,每孔50μL,同时设置空白对照孔(加100μLPBS)和阴性对照(加50μL单抗+50μLPBS洗液),37℃保温保湿45min;倾去一抗,洗涤3次,拍干;加酶标二抗:每孔加入100μL的l:10000稀释的HRP酶标记的山羊抗鼠IgG,37℃放置30min;倾去酶标二抗,洗涤3次,拍干;显色:每孔加底物显色液100μL,37℃避光反应15min;终止:每孔加入50μL终止液,终止反应;检测:测定波长为450nm处的吸光度值(A450)。
以吸光度百分比B/B0%(B代表不同浓度氟虫腈标准液的A450,B0代表零浓度氟虫腈标准液的A450)为纵坐标,以不同浓度氟虫腈标准液的对数[Lg(F)]为横坐标,绘制单克隆抗体的抑制曲线,曲线如图5。该单抗对氟虫腈的抑制率IC50为0.32μg/L。
(5)特异性测定
用竞争ELISA法检测抗氟虫腈单克隆抗体与克百威、多菌灵等结构类似物的交叉反应性,根据交叉反应率(Cross reaction,CR)判定抗氟虫腈单克隆抗体的特异性。CR=(F的IC50/各结构类似物的IC50)×100℅,结果见表2,该抗体与氟虫腈的CR(%)为100%,与其他结构类似物的CR(%)均小于0.01%。
表2抗氟虫腈单克隆抗体交叉反应结果
交叉反应物 | IC<sub>50</sub>/μg/L | 交叉反应率(%) |
氟虫腈 | 0.32 | 100.00 |
多菌灵 | >10<sup>4</sup> | <0.01 |
克百威 | >10<sup>4</sup> | <0.01 |
啶虫脒 | >10<sup>4</sup> | <0.01 |
甲萘威 | >10<sup>4</sup> | <0.01 |
百草枯 | >10<sup>4</sup> | <0.01 |
实施例3
将本发明的抗氟虫腈单克隆抗体用于酶联免疫试剂盒,本发明中试剂盒的检测原理是间接竞争ELISA方法。
将氟虫腈包被原包被于微孔板上,按需要取出板条,放置在酶标板上;将抗氟虫腈单克隆抗体工作液和酶标记抗抗体工作液按5:1的体积比混合;向包被了包被原F-OVA的酶标板孔内依次加入按照浓度梯度稀释的氟虫腈标准品或待测样品50μL、抗氟虫腈单克隆抗体工作液和酶标记抗抗体工作液的混合液50μL,轻轻振荡混匀,37℃避光孵育30min;将孔内液体甩干,用洗涤工作液(用去离子水将20×浓缩洗涤液20倍稀释)250μL/孔,洗涤4次,拍干;将显色液A和显色液B按1:1比例混合,100μL/孔加入显色,25℃避光孵育15min;加终止液50μL终止反应,酶标仪450nm下采用双波长450nm/630nm测定,根据标准曲线对待测样品进行定量或定性。
结果判定:(a)定量分析:分别计算不同浓度氟虫腈标准品和待测样品的平均吸光度值,不同浓度氟虫腈标准品或待测样品的吸光度值(B)除以0氟虫腈标准品的吸光度值(B0)再乘以100%,即为百分吸光度值,百分吸光度值=(B/B0)×100%。以百分吸光度值为纵坐标,氟虫腈标准品的浓度的对数为横坐标,绘制标准曲线。将待测样品的百分吸光度值代入标准曲线,即可求出待测样品中氟虫腈的浓度,再乘以稀释倍数即为待测样品中氟虫腈的实际含量。(b)定性分析:用待测样品的平均吸光度值和标准品的吸光度值相比较,即可得出待测样品中氟虫腈的浓度范围。本实施例的测试范围为0.078μg/L~2.5μg/L。
实施例4
将本发明的抗氟虫腈单克隆抗体应用于胶体金层析试纸条方法检测。
反应原理:采用竞争法对氟虫腈进行半定量检测,样品中存在的氟虫腈在沿试纸条上移过程中先与金颗粒标记的抗体F-3F6结合,固定在NC膜上的包被原与样品中的氟虫腈同时竞争结合金标抗体,T位置(检测线)的显色强弱与样品中残留氟虫腈的含量成反比,若样品中无氟虫腈残留,则金标抗体全部与包被原反应,试纸条的T线显色。
检测:取出氟虫腈胶体金层析试纸条,将样品端插入待测样品液中,插入深度不超过标记线,约15秒钟取出检测试纸条,水平放置,3分钟后观察判定检测结果,10分钟以后结果无效。
结果判定:包被膜上对应的质控区C位置(质控线)显示一条棕红色线,检测区T位置不显示棕红色线,表示检测结果为阳性,说明在待测样品液中含有氟虫腈;在包被膜上T、C位置显示有两条棕红色线,表示结果为阴性,说明在待测样品中不含氟虫腈;当质控区C不显示出棕红色条带,则无论检测区T显示出棕红色条带与否该试纸均判为无效。
实施例5
将本发明的抗氟虫腈单克隆抗体应用于倏逝波荧光免疫传感器方法检测。
反应原理:倏逝波荧光分析原理结合生物亲和反应原理,即用荧光标记的抗氟虫腈单克隆抗体共同竞争待测样品和光纤生物传感器表面上的氟虫腈,激发光引入光纤探头后产生倏逝波,使表面结合的荧光标记抗体发光。光电探测器收集到的荧光经数据处理,自动显示结果。
仪器包含:流动进样系统、光纤生物传感器、光路系统、信号处理系统。流动进样系统用于输送缓冲溶液、待测样品和再生溶液。光纤生物传感器表面通过光纤探头修饰氟虫腈的人工抗原而实现该药物的特异性检测。光纤探头修饰是利用N,N′-二琥珀酰亚胺基碳酸酯(DSC)取代戊二醛,将氟虫腈人工抗原(F-BSA)共价固定到光纤生物传感器表面。光路系统利用光开关控制激发光以1秒间隔交替进入模光纤。模光纤将激发光引入光纤探头后在光纤表面产生倏逝波,使表面结合的荧光标记抗体发光。光电探测器以1秒间隔检测收集到的荧光,经信号处理系统处理数据,自动显示结果。
检测:分别取50μL的不同浓度的氟虫腈溶液或待测样品与50μL的Cy5.5荧光标记抗氟虫腈单克隆抗体分别混合于0.5mL棕色离心管中,经过震荡仪震荡混合后于暗处静置避光反应6min。反应结束后进行仪器检测。按照预先调设好的程序,首先向光纤生物传感器中的光纤反应槽中通入10mM的PBS缓冲溶液清洗表面光纤(30s),使基线恢复平稳。之后系统程序将Cy5.5荧光标记抗氟虫腈单克隆抗体与不同浓度的氟虫腈溶液的各混合溶液或待测样品的混合溶液自动抽吸至光纤反应槽中。接着稳定反应4min,此时观测到检测信号逐渐上升并被电脑记录。接着泵入再生溶液(0.5%(pH 1.9)的SDS溶液)到光纤反应槽中再生3min,用于剥离已经结合在光纤表面的荧光标记抗体。最后通入10mM的PBS缓冲溶液清洗1min,以恢复光纤表面的pH值,至此检测结束。
结果判定:以空白样品(PBS)的荧光信号(e0)作基准,将不同浓度氟虫腈溶液与Cy5.5荧光标记抗氟虫腈单克隆抗体反应后检测所得的信号值(e)与之作比,得到标准化值(e/e0)。用Logistic函数进行拟合,建立标准化值(e/e0)与氟虫腈浓度的函数关系,即为标准检测曲线。用待测样品的平均信号值和标准品的信号值相比较,即可得出待测样品中氟虫腈的浓度。
在本发明中实施例3~5所用待测样品为经过预处理后的新鲜牛奶:取1mL新鲜牛奶于离心管中,加入5mL水,混匀;加入5mL乙腈,充分混匀,4000g以上离心5min;取1mL上清液,50~60℃水浴氮气吹干,加入1mL样品稀释液,充分涡旋30s。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (8)
1.一种杂交瘤细胞株F-3F6,保藏于中国典型培养物保藏中心,地址:中国武汉,武汉大学,保藏日期为2021年2月9日,保藏编号CCTCC NO:C202157;
所述杂交瘤细胞株F-3F6产生的抗氟虫腈单克隆抗体的亚型为IgG1。
2.一种抗氟虫腈单克隆抗体,其特征在于,由权利要求1所述的杂交瘤细胞株F-3F6产生。
3.一种权利要求2所述的抗氟虫腈单克隆抗体在非诊断和治疗目的的检测氟虫腈中的应用。
4.一种权利要求2所述的抗氟虫腈单克隆抗体用于制备检测氟虫腈的检测产品中的应用。
5.如权利要求4所述的应用,其特征在于,所述检测产品包括酶联免疫试剂盒、胶体金层析试纸条、倏逝波荧光免疫传感器。
6.一种检测氟虫腈的酶联免疫试剂盒,其特征在于,所述酶联免疫试剂盒包括权利要求2所述的抗氟虫腈单克隆抗体。
7.一种检测氟虫腈的胶体金层析试纸条,其特征在于,所述胶体金层析试纸条包括权利要求2所述的抗氟虫腈单克隆抗体。
8.一种检测氟虫腈的倏逝波荧光免疫传感器,其特征在于,所述倏逝波荧光免疫传感器包括权利要求2所述的抗氟虫腈单克隆抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110271245.8A CN113025580B (zh) | 2021-03-12 | 2021-03-12 | 一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体和抗体的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110271245.8A CN113025580B (zh) | 2021-03-12 | 2021-03-12 | 一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体和抗体的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113025580A CN113025580A (zh) | 2021-06-25 |
CN113025580B true CN113025580B (zh) | 2022-08-16 |
Family
ID=76470460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110271245.8A Active CN113025580B (zh) | 2021-03-12 | 2021-03-12 | 一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体和抗体的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113025580B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113636954B (zh) * | 2021-10-18 | 2021-12-31 | 天津国际生物医药联合研究院 | 一种氟虫腈人工抗原、制备方法及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101118216A (zh) * | 2007-09-07 | 2008-02-06 | 中国科学院长春光学精密机械与物理研究所 | 一种光纤生物探针及其制作方法和用途 |
CN109752531A (zh) * | 2017-11-01 | 2019-05-14 | 镇江华维检测技术有限公司 | 一种检测鸡蛋中氟虫腈的试剂盒及其检测方法 |
CN111187346B (zh) * | 2020-01-15 | 2023-05-05 | 江苏大学 | 一种检测氟虫腈及其代谢物的胶体金试纸条及其制备方法 |
CN111748528B (zh) * | 2020-07-08 | 2022-07-12 | 江南大学 | 一株分泌抗氟虫腈及其代谢物单克隆抗体的杂交瘤细胞株及其应用 |
-
2021
- 2021-03-12 CN CN202110271245.8A patent/CN113025580B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113025580A (zh) | 2021-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110167967A (zh) | 针对抗pd-l1抗体的独特型抗体及其用途 | |
CN104569404A (zh) | 直接竞争trfia法检测喹乙醇的方法 | |
Na et al. | Colloidal gold-based immunochromatographic strip assay for the rapid detection of bacitracin zinc in milk | |
CN108700576A (zh) | 制备抗体对的方法、试剂盒及试剂盒的应用和制备抗体对的系统 | |
Xie et al. | A high-affinity anti-salbutamol monoclonal antibody: key to a robust lateral-flow immunochromatographic assay | |
CN105131121B (zh) | 检测呋喃唑酮代谢物的单抗、elisa方法及试剂盒 | |
CN113025580B (zh) | 一种杂交瘤细胞株及其产生的抗氟虫腈单克隆抗体和抗体的应用 | |
CN109596839A (zh) | 人和肽素快速定量检测方法与试剂盒 | |
CN109705216B (zh) | 一种抗牛骨骼肌肌钙蛋白i单克隆抗体及其应用 | |
CN109810191B (zh) | 一种抗羊骨骼肌肌钙蛋白i单克隆抗体及其应用 | |
CN106380520B (zh) | 一种抗呋喃唑酮代谢物单克隆抗体及其应用 | |
CN106483300A (zh) | 一种检测呋喃唑酮代谢物的胶体金免疫层析试纸条及其制备方法与应用 | |
CN111072777B (zh) | 抗mHIN2蛋白抗体及其应用和包含其的试剂盒 | |
CN111072775B (zh) | 抗MntC蛋白抗体及其应用和包含其的试剂盒 | |
CN104749371A (zh) | 人肾母细胞瘤过度表达基因编码蛋白酶联免疫试剂盒 | |
CN102936584A (zh) | 氨基脲衍生物的单克隆抗体及其应用 | |
CN111018972B (zh) | 抗mSEB蛋白抗体及其应用和包含其的试剂盒 | |
CN103235125A (zh) | 莱克多巴胺、西马特罗二联胶体金试纸条及其制备方法与用途 | |
CN105440137B (zh) | 抗莱克多巴胺的抗体及其应用 | |
CN112250766A (zh) | 一种抗万古霉素单克隆抗体及其应用 | |
CN109633159B (zh) | 一种用于检测三聚氰胺含量的方法及其专用胶体金试纸 | |
CN109061150B (zh) | 一种检测甲霜灵的时间分辨荧光免疫层析试纸条及其制备方法和应用 | |
CN106754736B (zh) | 一种抗福莫特罗单克隆抗体及其应用 | |
CN116445421A (zh) | 一种杂交瘤细胞株及其产生的抗6-苄基腺嘌呤单克隆抗体和抗体的应用 | |
CN118406658A (zh) | 一种杂交瘤细胞株及其产生的抗4-氯苯氧乙酸单克隆抗体和抗体的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |